Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 851 - 900 out of 12,498

Document Document Title
WO/2012/142523A3
Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2- haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treat...  
WO/2013/096680A1
Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the...  
WO/2013/092447A1
The present invention relates to the use of nucleoside derivatives of formula (I) wherein the symbols are as the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.  
WO/2013/092481A1
The present disclosure relates to compounds of Formula (I): Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of using the compounds of Formula (I) and/or compositions comprising the compounds of...  
WO/2013/096679A1
Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are meth...  
WO/2013/090550A1
Compounds of formula (I) as shown in the disclosure, in which X, Y, and Z are defined herein. Also disclosed are pharmaceutical compositions and therapeutical methods related to these compounds.  
WO/2013/084165A1
The invention provides compounds of the formula:(I) which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.  
WO/2013/078517A1
A method for isolating aragonite and organic constituents from nacre-coated shell or pearl comprising the steps: exposing the nacreous layer of nacre-coated shell or pearl to an ionic liquid; and isolating the aragonite and organic const...  
WO/2012/140596A8
The present invention provides a compound of formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ...  
WO/2011/123621A3
The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2):Formula (1) and Formula (2). Another aspect of the invention relates to a method of inhibiting the expression...  
WO/2013/067666A1
Disclosed is a method for preparing zidovudine (B). The method comprises the following steps: 1) 2'-halothymidine (A) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group thereof in the 5'-posi...  
WO/2013/067664A1
The present invention relates to a method for preparing zidovudine (B). The method comprises the following steps: 1) 2'-halothymidine (A) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group th...  
WO/2011/139695A3
Provided herein are modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom. More particularly, modified 5' diphosphate nucleosides are provided that can be further modified at the 2' and 5' positions. In some emb...  
WO/2013/067669A1
Provided is a method for preparing zidovudine (C). The method comprises the following steps: 1) 2'-halothymidine (B) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group thereof in the 5'-posit...  
WO/2011/005860A3
The present invention provides nucleosides and oligonucleotides comprising a 5' phosphate mimics of formula (IVc) or (Vc). One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleot...  
WO/2012/177701A3
The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein theD02S derivatives having the following structure: wherein R1', R2' are each independe...  
WO/2011/139702A3
The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporatio...  
WO/2013/061105A2
The invention relates to compounds of formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof and processes for preparing them. In formula (I) X is -CH= or -N= or -N(R") -; Y is -N= or -N(R") -; R is an alk...  
WO/2013/036846A3
The present invention provides hydrophobic prodrugs of nucleic acid bases, nucleosides, and nucleotides. The compounds of the invention have a structure according to Formula I. Methods for the hypomethylation of oligonucleotides, treatme...  
WO/2010/084115A3
Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; as defined herein, are described for use in the prevention and/or treatment of HCV infections. Novel compounds of the formula (I) and pharmaceutical form...  
WO/2013/056046A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2013/055252A1
The invention relates to the field of molecular biology, virology and medicine and concerns novel biologically active compounds, more specifically salts of carbamoyl phosphonic acid esters of the general formula given in the description....  
WO/2013/047567A1
Flavin adenine dinucleotide or a salt thereof significantly curbs the decline in viable cell count of corneal epithelial cells induced by ultraviolet radiation, and thus can act as an inhibitor of corneal epithelial cell death induced by...  
WO/2013/044811A1
The present invention relates to the field of medical technology, and in particular relates to a kind of gemcitabine amide derivative with a novel structure. The new compounds of the present invention are very active with regard to many ...  
WO/2013/040257A1
The present invention relates generally to 3'-OH unblocked nucleotides and nucleosides labeled and unlabeled with 5-methoxy-substituted nitrobenzyl-based photocleavable terminating groups for use in methods and systems related to DNA and...  
WO/2013/039855A1
Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered eith...  
WO/2013/036868A1
Synthesis and uses of conformationally restricted nucleomonomers (CRN) to prepare nucleic acid compounds. Methods for preparing nucleomonomers for nucleic acid compounds in high yields and in multi-gram scale for therapeutic modalities u...  
WO/2013/036846A2
The present invention provides hydrophobic prodrugs of nucleic acid bases, nucleosides, and nucleotides. The compounds of the invention have a structure according to Formula I. Methods for the hypomethylation of oligonucleotides, treatme...  
WO/2013/033705A2
A theranostic agent for inhibiting translesion DNA replication comprises natural adenine ribose analog having formula I.  
WO/2013/026424A1
A method for the' preparation of 2-[4-[(methylamino)carbonyl]-1-H-pyrazol-1- yl]adenosine monohydrate of formula I by reaction of 2-(4-methoxycarbonylpyrazol-1-yl) adenosine of formula III with a solution of methylamine in a non-aqueous ...  
WO/2012/166705A3
Described herein are hydrogelators that include a nucleobase, an amino acid, and a glycoside. The hydrogelators have increased resistance to proteases and can self-assemble into supramolecular nanofibers or hydrogels. The supramolecular ...  
WO/2013/027843A1
Provided is a glucoside compound that can be produced inexpensively and is capable of imparting a phosphoramidite with which a nucleic acid can be produced at a high yield and high purity. The glucoside compound is represented by chemica...  
WO/2012/158811A3
The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikunguny...  
WO/2013/026142A1
The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II) processes for making these compounds, and the use thereof in the chemi...  
WO/2013/023626A1
A method for the preparation of 2-(4-methoxycarbonylpyrazol-l-yl)adenosine of formula la and 2-(4-ethoxycarbonylpyrazol-l-yl)adenosine of formula lb by reaction of 2- hydrazinoadenosine of formula III and the sodium salt of 3,3-dimethoxy...  
WO/2012/142093A3
The present invention relates to 2'-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3are as defined herein. The present invention also relates to compositi...  
WO/2013/013404A1
The present invention relates to a water soluble derivative of camptothecin and preparation method therefor, the derivative having a structure of formula I and being appropriate in water solubility, and having anti-cancer activity and st...  
WO/2013/013009A2
The present invention provides 2',3'-dideoxy-2'-fluoro-α-2'-C- methylnucleosides, their prodrugs, and therapeutic use thereof as anti-HCV agents. The present invention also provides processes and intermediates for the preparation of the...  
WO/2012/158552A3
The present invention relates to 2'-Fluoro-6'-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease...  
WO/2013/010573A1
The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related...  
WO/2013/009737A1
The present invention relates to 5'-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R1, R2, R3 and R3' are as defined herein. The present invention also relates to compositio...  
WO/2013/007992A1
3-(2',3'-dideoxy-ribo-β-L-furanosyl)[2,3-d]pyrimidin-2(3H)- one derivatives comprising 6-substitutents on the base moiety are shown to have anti-viral properties, particularly with respect to vaccinia and measles. The compounds have unn...  
WO/2013/009735A1
The present invention relates to 5'-Substituted Nucleoside Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, Z, R1, R2, R3 and R3' are as defined herein. The present invention also relates to...  
WO/2012/177701A2
The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein theD02S derivatives having the following structure: wherein R1', R2' are each independe...  
WO/2011/083484A3
The present invention relates to improved process for the preparation of lamivudine or emtricitabine. Thus, (1'R,2'S,5'R)-menthyl- 5(R,S)-acetoxy-[1,3]-oxathiolane-2(R)-carboxylate is reacted with N-propinoyl cytosine in hexamethyl disil...  
WO/2012/175516A1
The present invention concerns a new family of analogues of NADP+ or NADPH, their preparation and their application in therapeutics.  
WO/2012/143624A3
The invention relates to acadesine derivatives as a drug, as well as to said derivatives for the treatment of cancer and particularly for the treatment of chronic myeloid leukemia (CML). The invention further relates to a product contain...  
WO/2012/170347A1
The present invention provides novel bicyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the bicyclic nucleosides into an oligomeric compound is expected to enhance one or more properties of ...  
WO/2012/168348A1
The application provides methods for treatment or prophylaxis of dengue virus mediated diseases with compounds of Formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein. The application further discloses met...  
WO/2012/166705A2
Described herein are hydrogelators that include a nucleobase, an amino acid, and a glycoside. The hydrogelators have increased resistance to proteases and can self-assemble into supramolecular nanofibers or hydrogels. The supramolecular ...  

Matches 851 - 900 out of 12,498